Edition:
United Kingdom

Juno Therapeutics Inc (JUNO.OQ)

JUNO.OQ on NASDAQ Stock Exchange Global Select Market

86.64USD
8:59pm GMT
Change (% chg)

$1.66 (+1.95%)
Prev Close
$84.98
Open
$86.74
Day's High
$86.75
Day's Low
$86.57
Volume
1,526,785
Avg. Vol
903,458
52-wk High
$86.75
52-wk Low
$19.62

Latest Key Developments (Source: Significant Developments)

Juno Therapeutics Says If Deal Terminated By Co Or Celgene, Fee Of $300 Mln May Be Payable By Co To Celgene
Monday, 22 Jan 2018 

Jan 22 (Reuters) - Celgene Corp ::JUNO THERAPEUTICS SAYS IF DEAL TERMINATED BY CO OR CELGENE UPON SPECIFIED CONDITIONS, FEE OF $300 MILLION MAY BE PAYABLE BY CO TO CELGENE - SEC FILING.JUNO THERAPEUTICS SAYS DEAL AGREEMENT PROVIDES CELGENE TO HAVE TO PAY CO REVERSE TERMINATION FEE OF $600 MILLION IF DEAL TERMINATED UNDER SOME CONDITIONS.  Full Article

Celgene To Acquire Remaining Shares Of Juno Therapeutics For $87 Per Share
Monday, 22 Jan 2018 

Jan 22 (Reuters) - Celgene Corp ::CELGENE CORPORATION TO ACQUIRE JUNO THERAPEUTICS, INC., ADVANCING GLOBAL LEADERSHIP IN CELLULAR IMMUNOTHERAPY.CELGENE CORPORATION TO ACQUIRE JUNO THERAPEUTICS, INC., ADVANCING GLOBAL LEADERSHIP IN CELLULAR IMMUNOTHERAPY.CELGENE CORP - DEAL FOR $87 PER SHARE.CELGENE CORP - REAFFIRMING 2020 FINANCIAL TARGETS OF $19B-$20B IN TOTAL NET PRODUCT SALES AND ADJUSTED EPS GREATER THAN $12.50.CELGENE CORP - ‍TRANSACTION WAS APPROVED BY BOARDS OF DIRECTORS OF BOTH COMPANIES​.CELGENE CORP - JCAR017 IS EXPECTED TO BE SIGNIFICANT GROWTH DRIVER BEYOND 2020 WITH POTENTIAL GLOBAL PEAK SALES OF APPROXIMATELY $3 BILLION.CELGENE CORP - CELGENE WILL PAY APPROXIMATELY $9 BILLION, NET OF CASH AND MARKETABLE SECURITIES ACQUIRED AND JUNO SHARES ALREADY OWNED BY CELGENE.CELGENE CORP - ‍ACQUISITION IS EXPECTED TO BE DILUTIVE TO ADJUSTED EPS IN 2018 BY APPROXIMATELY $0.50​.CELGENE CORP - ‍REGULATORY APPROVAL FOR JCAR017 IN U.S. IS EXPECTED IN 2019 WITH POTENTIAL GLOBAL PEAK SALES OF APPROXIMATELY $3 BILLION​.CELGENE CORP - DEAL ‍IS EXPECTED TO BE INCREMENTALLY ADDITIVE TO NET PRODUCT SALES IN 2020​.CELGENE CORP - CELGENE EXPECTS TO FUND TRANSACTION THROUGH A COMBINATION OF EXISTING CASH AND NEW DEBT.CELGENE CORP - REGULATORY APPROVAL FOR JCAR017 IN U.S. IS EXPECTED IN 2019.  Full Article

Celgene Is In Talks To Buy Juno Therapeutics -WSJ Reporter Tweet‍​
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - :CELGENE IS IN TALKS TO BUY JUNO THERAPEUTICS -WSJ REPORTER TWEET‍​.  Full Article

Juno Therapeutics And Thermo Fisher Scientific Announce CAR T Manufacturing Partnership
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Juno Therapeutics Inc ::JUNO THERAPEUTICS AND THERMO FISHER SCIENTIFIC ANNOUNCE CAR T MANUFACTURING PARTNERSHIP.JUNO THERAPEUTICS - OBTAINED RIGHTS TO USE CTS DYNABEADS CD3/CD28 MAGNETIC BEADS FOR CLINICAL, COMMERCIAL MANUFACTURING PROCESSES FOR CAR T THERAPIES.JUNO THERAPEUTICS INC - NO OTHER TERMS FROM THIS TRANSACTION WERE DISCLOSED.  Full Article

Juno Therapeutics Signs Licensing Agreements With Lilly, Oncotracker, And Fred Hutchinson Cancer Research Center
Wednesday, 6 Dec 2017 

Dec 6 (Reuters) - Juno Therapeutics Inc ::JUNO THERAPEUTICS SIGNS LICENSING AGREEMENTS WITH LILLY, ONCOTRACKER, AND FRED HUTCHINSON CANCER RESEARCH CENTER TO ADVANCE ITS BCMA-DIRECTED ENGINEERED T CELL PROGRAM IN MULTIPLE MYELOMA WITH GAMMA SECRETASE INHIBITION.JUNO THERAPEUTICS - THREE LICENSE DEALS TO ADVANCE PROGRAM IN MULTIPLE MYELOMA USING GAMMA SECRETASE INHIBITORS WITH BCMA-DIRECTED CAR T CELLS.JUNO THERAPEUTICS INC - THROUGH ITS AGREEMENT WITH ELI LILLY AND COMPANY, JUNO WILL ACQUIRE A LICENSE TO GSI KNOWN AS LY3039478.JUNO THERAPEUTICS- CO TO ALSO GAIN RIGHTS TO INTELLECTUAL PROPERTY WITHIN FIELD OF COMBINATIONS OF GSIS, BCMA-DIRECTED ENGINEERED T CELLS IN OTHER DEALS.JUNO THERAPEUTICS INC - NO OTHER TERMS FROM THESE THREE TRANSACTIONS WERE DISCLOSED.  Full Article

Juno Therapeutics reports Q3 adjusted loss per share ‍$0.73​
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Juno Therapeutics Inc :Juno Therapeutics reports third quarter 2017 financial results.Juno Therapeutics Inc - qtrly ‍revenue $44.8 million versus $20.8 million​.Juno Therapeutics Inc - qtrly loss per share ‍$1.12​.Juno Therapeutics Inc - qtrly adjusted loss per share ‍$0.73​.Juno Therapeutics Inc - ‍expects to be in lower half of 2017 cash burn guidance​.Q3 earnings per share view $-0.80, revenue view $16.2 million -- Thomson Reuters I/B/E/S.  Full Article

Juno Therapeutics and Trianni sign licensing agreement for use of Trianni Transgenic Mouse platform
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - Juno Therapeutics Inc : :Trianni and Juno Therapeutics sign licensing agreement for use of Trianni Transgenic Mouse platform.Juno - to use Trianni Mouse with its single cell sequencing technology to identify fully-human binders for conversion to chimeric antigen receptors.Juno Therapeutics Inc - ‍no financial details were disclosed​.  Full Article

Juno Therapeutics reports Q2 loss per share $0.64
Thursday, 4 Aug 2016 

Juno Therapeutics Inc : Juno Therapeutics reports second quarter 2016 financial results . Reaffirms cash burn guidance . Qtrly revenue $27.6 million versus $12.5 million . Qtrly loss per share $0.64 .Q2 earnings per share view $-0.41, revenue view $14.3 million -- Thomson Reuters I/B/E/S.  Full Article

Juno Therapeutics Inc - collaboration includes BCMA CAR constructs with fully-human binding domains
Thursday, 4 Aug 2016 

Juno Therapeutics Inc : Collaboration includes BCMA CAR constructs with fully-human binding domains .Juno Therapeutics announces multiple myeloma partnership with memorial sloan kettering cancer center and eureka therapeutics for developing cart cell immunotherapy against multiple novel targets.  Full Article

Juno Therapeutics adds adenosine receptor antagonist through acquisition of redoxtherapies
Thursday, 14 Jul 2016 

Juno Therapeutics Inc : Juno Therapeutics adds adenosine receptor antagonist through acquisition of redoxtherapies . Intend to use in combination with engineered t cells . Upfront consideration for redoxtherapies acquisition was $10 million in cash . Redox is also eligible to receive payments upon achievement of undisclosed clinical, regulatory, and commercial milestones . Acquisition provides Juno with an exclusive license to vipadenant, a small molecule adenosine a2a (a2a) receptor antagonist .Intends to explore adenosine molecule in combination with engineered t cell platform, may over time explore in other areas as well.  Full Article

BRIEF-Celgene Receives Antitrust Clearance For Juno Acquisition

* CELGENE CORP - ‍CELGENE EXPECTS JUNO TRANSACTION TO CLOSE IN Q1 OF 2018​ Source text for Eikon: Further company coverage: